Back to top
more

Biogen (BIIB)

(Real Time Quote from BATS)

$128.58 USD

128.58
615,979

-0.76 (-0.59%)

Updated Aug 7, 2025 01:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks News

Mark Vickery headshot

Top Stock Reports for Boeing, AbbVie & U.S. Bancorp

Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), AbbVie (ABBV), and U.S. Bancorp (USB).

    Arpita Dutt headshot

    Better Days Ahead for the Pharma Sector?

    Sales, R&D, strong results, and a higher number of FDA approvals.

      Zacks Equity Research

      Nektar (NKTR) Stock Rallied Almost 50% This Year: Here's Why

      Shares of Nektar Therapeutics (NKTR) are up almost 48% this year so far, outperforming the Zacks classified Medical-Drugs industry's registered increase of 3.6% during this period.

        Kevin Cook headshot

        Bear of the Day: Bioverativ (BIVV)

        Biogen spin-off just reported its first quarter and made an acquisition, but estimates were trimmed

          Zacks Equity Research

          Biogen Loses Top Executive Again, CFO Clancy to Join Alexion

          Biogen Inc.'s (BIIB) chief financial officer (CFO) for the last 10 years, Paul Clancy, is joining Alexion Pharmaceuticals, Inc. (ALXN) next month.

            Zacks Equity Research

            Biogen/Ionis Spinraza Granted Marketing Authorization in EU

            Biogen Inc. (BIIB) announced granting of marketing authorization to its marketed drug Spinraza (nusinersen) by European Commission under the accelerated assessment program for treating patients with 5q spinal muscular atrophy.

              Arpita Dutt headshot

              5 Drug Stocks in Focus on World MS Day

              Life with MS -- this world MS day, here's a look at 5 stocks including Biogen (BIIB) that are key players in the multiple sclerosis (MS) market.

                Zacks Equity Research

                The Zacks Analyst Blog Highlights: UnitedHealth Group, Union Pacific, Biogen, United Technologies and Accenture

                The Zacks Analyst Blog Highlights: UnitedHealth Group, Union Pacific, Biogen, United Technologies and Accenture

                  Zacks Equity Research

                  Are Nektar's (NKTR) Key Drugs Set to Drive Growth in 2017?

                  On May 29, 2017, we issued an updated report on Nektar Therapeutics (NKTR).

                    Arpita Dutt headshot

                    Biotech Stock Roundup: Puma Soars on Advisory Panel Vote, Priority Review for Kite Drug

                    Key highlights in the biotech sector include a favorable advisory panel vote for Puma (PBYI) and positive data and positive data from companies like Inovio and BioCryst.

                      Mark Vickery headshot

                      Top Research Reports for UnitedHealth Group, Union Pacific & Biogen

                      Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Inc (UNH), Union Pacific Corporation (UNP) and Biogen Inc (BIIB).

                        Zacks Equity Research

                        Merck (MRK) Buys Rights to Anti-tau Antibody for Alzheimer

                        Merck & CO, Inc. (MRK) announced that it has bought exclusive worldwide license from Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical anti-tau antibody.

                          Zacks Equity Research

                          Biogen (BIIB) Down 9.5% Since Earnings Report: Can It Rebound?

                          BIIB reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                            Zacks Equity Research

                            Biogen's Fampyra Conditional Approval Converted to Standard

                            Biogen Inc. (BIIB) announced that the conditional marketing authorization for its drug Fampyra for improvement of walking in multiple sclerosis (MS) patients in the EU has been converted to a standard marketing approval.

                              Arpita Dutt headshot

                              Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal

                              Quite a few deals were announced this week including by companies like Biogen (BIIB).

                                Zacks Equity Research

                                Biogen (BIIB) Buys Stroke Candidate Cirara for $120M

                                Biogen Inc. (BIIB) announced the acquisition of Remedy Pharmaceuticals' phase III candidate, Cirara for the treatment of large hemispheric stroke (LHI).

                                  Zacks Equity Research

                                  The Zacks Analyst Blog Highlights: Exxon Mobil, JPMorgan, Union Pacific, Biogen and Becton Dickinson

                                  The Zacks Analyst Blog Highlights: Exxon Mobil, JPMorgan, Union Pacific, Biogen and Becton Dickinson

                                    Zacks Equity Research

                                    What's in the Cards for Ionis (IONS) this Earnings Season?

                                    Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report first-quarter 2017 results on May 9. Last quarter, the company recorded a positive earnings surprise of 265%. Let's see how things are shaping up for this announcement.

                                      Mark Vickery headshot

                                      Top Research Reports for May 4, 2017

                                      Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil (XOM), JPMorgan (JPM) and Union Pacific (UNP).

                                        Zacks Equity Research

                                        Acorda (ACOR) Q1 Loss Wider Than Expected, Revenues Miss

                                        Acorda Therapeutics, Inc. (ACOR) reported loss of 25 cents per share in the first quarter of 2017 (including the impact of stock-based compensation expenses), wider than the Zacks Consensus Estimate of a loss of 16 cents.

                                          Zacks Equity Research

                                          Lilly (LLY) Tops Q1 Earnings, Misses Sales, Shares Down

                                          Eli Lilly and Company (LLY) reported first-quarter 2017 adjusted earnings per share of 98 cents, which beat the Zacks Consensus Estimate of 96 cents by 2.1%.

                                            Zacks Equity Research

                                            Biogen (BIIB) Q1 Earnings & Sales Top, Spinraza Sales Strong

                                            Biogen Inc. (BIIB) reported better-than-expected results in the first-quarter of 2017. The company surpassed expectations both for earnings and sales.

                                              Zacks Equity Research

                                              Biogen (BIIB) Beats on Q1 Earnings and Revenue

                                              BIIB???s first quarter 2017 earnings were better-than expected. The company posted earnings of $5.20 per share while our consensus called for EPS of $4.97.

                                                Arpita Dutt headshot

                                                3 Key Factors to Look Out for in Biogen's Q1 Results

                                                With Biogen (BIIB) set to report Q1 results tomorrow, here is a look at 3 key factors investors will be focused on apart from earnings and revenue.

                                                  Zacks Equity Research

                                                  Drug Stocks Q1 Earnings Releases on Apr 25: LLY, BIIB, NVS

                                                  As the Q1 earnings season gets in full swing this week, we believe this quarter is on track to see the highest growth in almost three years.